scispace - formally typeset
F

Frank A. Anania

Researcher at Emory University

Publications -  74
Citations -  11740

Frank A. Anania is an academic researcher from Emory University. The author has contributed to research in topics: Fatty liver & Hepatic stellate cell. The author has an hindex of 39, co-authored 74 publications receiving 10528 citations. Previous affiliations of Frank A. Anania include Silver Spring Networks & Veterans Health Administration.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

Xiaokun Ding, +4 more
- 01 Jan 2006 - 
TL;DR: Exendin‐4 appears to effectively reverse hepatic steatosis in ob/ob mice by improving insulin sensitivity and the data suggest that GLP‐1 proteins in liver have a novel direct effect on hepatocyte fat metabolism.
Journal ArticleDOI

Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells

Neeraj K. Saxena, +6 more
- 15 Mar 2007 - 
TL;DR: Data indicate that leptin promotes hepatocellular carcinoma growth, invasiveness, and migration and implicate the JAK/STAT pathway as a critical mediator of leptin action, which has potential clinical implications for hepatitis C progression in obese patients.
Journal ArticleDOI

Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

Nitika A. Gupta, +6 more
- 01 May 2010 - 
TL;DR: It appears that exendin‐4 has the same beneficial effects in vitro as those seen in the previously published in vivo study in ob/ob mice, directly reducing hepatocyte steatosis.
Journal ArticleDOI

Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.

Anna Alisi, +9 more
- 01 Jun 2014 - 
TL;DR: Gut microbiota modifiers may have beneficial effects of non‐alcoholic fatty liver disease (NAFLD) but randomised controlled trials (RCT) are lacking in children.